Abstract
Background: Cardio-cerebral-vascular diseases, including myocardial infarction, atherosclerosis, hypertension, and stroke etc, are the major reasons for morbidity and mortality all over the world. Recent studies showed that inflammation exerts an important impact on the pathogenesis and development of cardio-cerebral-vascular diseases. “The cholinergic anti-inflammatory pathway”, mainly modulated through α7 nicotinic acetylcholine receptor (α7nAChR), has attracted much attention.
Objective: The purpose of this review was to discuss the role of α7nAChR during the pathological processes in myocardial infarction, atherosclerosis, hypertension and stroke.
Results: Most of the existing literatures involved in studying on myocardial infarction, atherosclerosis, hypertension and stroke showed that activation of α7nAChR might be a potential strategy for the prevention and treatment of these diseases.
Conclusion: Targeting α7nAChR to combat inflammation might be a novel therapy in cardiocerebral- vascular diseases.
Keywords: α7nAChR, inflammation, anti-inflammation target, cardio-cerebral-vascular diseases, myocardial infarction, hypertension.
Current Drug Targets
Title:Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Volume: 18 Issue: 15
Author(s): Hui Fu, Min Ni, Ji-Kuai Chen, Ting Zhao, Ya-Ping Deng, Dong-Jie Li, Guo-Jun Jiang*Fu-Ming Shen*
Affiliation:
- Department of Pharmacy, Zhejiang Xiaoshan Hospital, 728 Yucaibei Road, Hangzhou, Zhejiang 311202,China
- Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University, 301 Middle Yanchang Road, Shanghai 200072,China
Keywords: α7nAChR, inflammation, anti-inflammation target, cardio-cerebral-vascular diseases, myocardial infarction, hypertension.
Abstract: Background: Cardio-cerebral-vascular diseases, including myocardial infarction, atherosclerosis, hypertension, and stroke etc, are the major reasons for morbidity and mortality all over the world. Recent studies showed that inflammation exerts an important impact on the pathogenesis and development of cardio-cerebral-vascular diseases. “The cholinergic anti-inflammatory pathway”, mainly modulated through α7 nicotinic acetylcholine receptor (α7nAChR), has attracted much attention.
Objective: The purpose of this review was to discuss the role of α7nAChR during the pathological processes in myocardial infarction, atherosclerosis, hypertension and stroke.
Results: Most of the existing literatures involved in studying on myocardial infarction, atherosclerosis, hypertension and stroke showed that activation of α7nAChR might be a potential strategy for the prevention and treatment of these diseases.
Conclusion: Targeting α7nAChR to combat inflammation might be a novel therapy in cardiocerebral- vascular diseases.
Export Options
About this article
Cite this article as:
Fu Hui, Ni Min, Chen Ji-Kuai, Zhao Ting, Deng Ya-Ping, Li Dong-Jie, Jiang Guo-Jun*, Shen Fu-Ming*, Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450116666150825123247
DOI https://dx.doi.org/10.2174/1389450116666150825123247 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design The Role of Metabolism in Toxicity of Polycyclic Aromatic Hydrocarbons and their Non-genotoxic Modes of Action
Current Drug Metabolism L-Arginine in the Prevention and Treatment of Cardiovascular Disease: From Basic to Clinical Research Studies
Vascular Disease Prevention (Discontinued) Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Sudden Infant Death Syndrome: Implications of Altered Physiological Control During Sleep
Current Pediatric Reviews Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Editorial (Hot Topic: Cardiovascular Disease Biomarkers: from Tradition to Modernity)
Current Topics in Medicinal Chemistry EP2300 Compounds: Focusing on the Antiatherosclerotic Properties of Squalene Synthase Inhibitors
Current Pharmaceutical Design